![Keith Gottesdiener](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Keith Gottesdiener
Direttore/Membro del Consiglio presso
SEPTERNA, INC.
Patrimonio netto: 16 M $ in data 30/06/2026
Profilo
Keith M.
Gottesdiener is currently Chief Executive Officer at Excellentia Global Partners, Independent Director at Septerna, Inc. starting in 2025, Director at Cardurion Pharmaceuticals, Inc., and Senior Advisor at Samsara BioCapital LLC.
Former roles include President, Chief Executive Officer & Director at Prime Medicine, Inc. from 2020 to 2025; Chief Executive Officer & Director at Allergan GI Corp.
from 2011 to 2014; President, Chief Executive Officer & Director at Rhythm Pharmaceuticals, Inc. from 2017 to 2020; Independent Director at Intercept Pharmaceuticals, Inc. from 2016 to 2023; Associate Clinical Professor-Medicine at The Trustees of Columbia University in The City of New York from 1986 to 1995; Vice President at Merck Research Laboratories Massachusetts LLC from 1995 to 2011; Associate at Columbia University College of Physicians & Surgeons from 1987 to 2004; and Head-Late Development at Schering-Plough Corp.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
PRIME MEDICINE, INC. 2,53% | 31/03/2026 | 4.361.078 ( 2,53% ) | 16 M $ | 30/06/2026 |
SEPTERNA, INC. -.--% | 26/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Posizioni attive di Keith Gottesdiener
| Società | Posizione | Inizio |
|---|---|---|
| SEPTERNA, INC. | Direttore/Membro del Consiglio | 25/09/2025 |
Cardurion Pharmaceuticals, Inc.
 Cardurion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of heart failure and cardiovascular diseases | Direttore/Membro del Consiglio | - |
Excellentia Global Partners
 Excellentia Global Partners Financial ConglomeratesFinance Provides investment and advisory services | Amministratore Delegato | - |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara BioCapital invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and pharmaceuticals. It provides early and later stage capital requirements. | Consulente / Consigliere | - |
Precedenti posizioni note di Keith Gottesdiener
| Società | Posizione | Fine |
|---|---|---|
| PRIME MEDICINE, INC. | Amministratore Delegato | 18/05/2025 |
| INTERCEPT PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 08/11/2023 |
| RHYTHM PHARMACEUTICALS, INC. | Amministratore Delegato | 28/03/2020 |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Corporate Officer/Principal | 01/10/2011 |
Columbia University College of Physicians & Surgeons
 Columbia University College of Physicians & Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2004 |
Formazione di Keith Gottesdiener
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
91
Relazioni di 1° grado
14
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 14 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Intercept Pharmaceuticals, Inc.
 Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
Rhythm Pharmaceuticals, Inc.
 Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Develops peptide therapeutics for the treatment of gastrointestinal diseases | Health Technology |
Columbia University College of Physicians & Surgeons
Columbia University College of Physicians & Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Excellentia Global Partners
Excellentia Global Partners Financial ConglomeratesFinance Provides investment and advisory services | Finance |
Cardurion Pharmaceuticals, Inc.
Cardurion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of heart failure and cardiovascular diseases | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara BioCapital invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and pharmaceuticals. It provides early and later stage capital requirements. | Finance |
Prime Medicine, Inc.
 Prime Medicine, Inc. BiotechnologyHealth Technology Develops CRISPR gene editing technology | Health Technology |
Septerna, Inc.
 Septerna, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor oral small molecule products for the treatment of hypoparathyroidism | Health Technology |
